Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo.

[1]  A. Trkola,et al.  Antibody Neutralization-Resistant Primary Isolates of Human Immunodeficiency Virus Type 1 , 1998, Journal of Virology.

[2]  J. Hansen,et al.  Chemokine receptor polymorphism and autologous neutralizing antibody response in long-term HIV-1 infection. , 1998, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[3]  Q. Sattentau,et al.  Neutralization of Human Immunodeficiency Virus Type 1 by Antibody to gp120 Is Determined Primarily by Occupancy of Sites on the Virion Irrespective of Epitope Specificity , 1998, Journal of Virology.

[4]  D. Montefiori,et al.  Passive immunization of newborn rhesus macaques prevents oral simian immunodeficiency virus infection. , 1998, The Journal of infectious diseases.

[5]  S. Zolla-Pazner,et al.  Passive immunization with a human immunodeficiency virus type 1-neutralizing monoclonal antibody in Hu-PBL-SCID mice: isolation of a neutralization escape variant. , 1998, The Journal of infectious diseases.

[6]  D. Richman,et al.  Human Immunodeficiency Virus Replication and Genotypic Resistance in Blood and Lymph Nodes after a Year of Potent Antiretroviral Therapy , 1998, Journal of Virology.

[7]  C. Raker,et al.  thy/liv-SCID-hu mice: a system for investigating the in vivo effects of multidrug therapy on plasma viremia and human immunodeficiency virus replication in lymphoid tissues. , 1998, The Journal of infectious diseases.

[8]  C. Barbas,et al.  Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1 , 1997, Nature Medicine.

[9]  D. Montefiori,et al.  Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection. , 1997, The Journal of infectious diseases.

[10]  D R Burton,et al.  Human immunodeficiency virus type 1 mutants that escape neutralization by human monoclonal antibody IgG1b12. off , 1997, Journal of virology.

[11]  J. Bradac,et al.  Evaluation of monoclonal antibodies to human immunodeficiency virus type 1 primary isolates by neutralization assays: performance criteria for selecting candidate antibodies for clinical trials. AIDS Clinical Trials Group Antibody Selection Working Group. , 1997, The Journal of infectious diseases.

[12]  V. Roberts,et al.  Humanization and molecular modeling of the anti-CD4 monoclonal antibody, OKT4A. , 1996, Journal of immunology.

[13]  A. Perelson,et al.  HIV-1 Dynamics in Vivo: Virion Clearance Rate, Infected Cell Life-Span, and Viral Generation Time , 1996, Science.

[14]  A. Trkola,et al.  Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1 , 1996, Journal of virology.

[15]  D. Ho,et al.  HIV-1 dynamics in vivo. , 1995, Journal of biological regulators and homeostatic agents.

[16]  Q. Sattentau,et al.  Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer , 1995, The Journal of experimental medicine.

[17]  C. Barbas,et al.  Protection against HIV‐1 infection in hu‐PBL-SCID mice by passive immunization with a neutralizing human monoclonal antibody against the gp120 CD4‐binding site , 1995, AIDS.

[18]  J. Safrit,et al.  Pre- and postexposure protection against human immunodeficiency virus type 1 infection mediated by a monoclonal antibody. , 1995, The Journal of infectious diseases.

[19]  J. Coffin,et al.  HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy , 1995, Science.

[20]  A. Perelson,et al.  Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection , 1995, Nature.

[21]  G. Pantaleo,et al.  Effect of anti‐V3 antibodies on cell‐free and cell‐to‐cell human immunodeficiency virus transmission , 1995, European journal of immunology.

[22]  D R Burton,et al.  Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. , 1994, Science.

[23]  D R Burton,et al.  Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1 , 1994, Journal of virology.

[24]  G Himmler,et al.  A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1 , 1993, Journal of virology.

[25]  D E Mosier,et al.  Rapid loss of CD4+ T cells in human-PBL-SCID mice by noncytopathic HIV isolates. , 1993, Science.

[26]  J. Hansen,et al.  Autologous HIV‐1 Neutralizing Antibodies: Emergence of Neutralization‐Resistant Escape Virus and Subsequent Development of Escape Virus Neutralizing Antibodies , 1992, Journal of acquired immune deficiency syndromes.

[27]  D R Burton,et al.  A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[28]  D E Mosier,et al.  Human immunodeficiency virus infection of human-PBL-SCID mice. , 1991, Science.

[29]  Q. Sattentau,et al.  Dissociation of gp120 from HIV-1 virions induced by soluble CD4. , 1990, Science.

[30]  M. Wainberg,et al.  Neutralization of multiple HIV-1 isolates from a single subject by autologous sequential sera. , 1990, The Journal of infectious diseases.

[31]  J. Albert,et al.  Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera. , 1990, AIDS.

[32]  D. Brahams.  Human immunodeficiency virus and the law. , 1987, Lancet.

[33]  H. Vinters,et al.  Dual infection of the central nervous system by AIDS viruses with distinct cellular tropisms. , 1987, Science.

[34]  D. Burton,et al.  The antibody response in HIV-1 infection. , 1997, AIDS.

[35]  J. Moore,et al.  HIV-1 neutralization: the consequences of viral adaptation to growth on transformed T cells. , 1995, AIDS.

[36]  J. Safrit,et al.  hu-PBL-SCID mice can be protected from HIV-1 infection by passive transfer of monoclonal antibody to the principal neutralizing determinant of envelope gp120. , 1993, AIDS.

[37]  C. Cheng‐Mayer,et al.  Distinct Biological Properties of Human and Serological , 2004 .